Form 4: Celldex Therapeutics SVP, Chief Medical Officer, Diane C. Young, Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, exercised stock options and sold the acquired shares on June 11, 2024.
Summary
- On June 11, 2024, Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, exercised incentive stock options to acquire 15,000 shares of common stock at a price of $2.71 per share.
- Following the exercise, Ms. Young disposed of the 15,000 shares.
- After the reported transaction, Ms. Young directly owns 17,115 shares of Celldex Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a routine disclosure of insider trading activity.
Industry Context
This is a standard Form 4 filing, reflecting insider transactions. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 07/08/2023 | Option fully vested |
| 06/11/2024 | Transaction Date: Exercise of stock options and disposal of shares |
| 06/13/2024 | Date of Form 4 Filing |
| 07/08/2029 | Expiration Date of Incentive Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.